logo
  

Garmin Gains 11% Over Increase In Q1 Profit

Stock of Garmin Ltd. (GRMN) is rising over 11 percent on Wednesday after reporting first-quarter profit of $275.96 million, or $1.43 per share compared to $202.33 million, or $1.05 per share, in last year's first quarter.

On adjusted basis, profit amounted to $274.04 million or $1.42 per share, which was higher than analysts' expectation of $1.01 per share.

The company's revenue rose to $1.38 billion from $1.15 billion last year.

Currently, Garmin's stock is rising 11.30 percent, to $160.99 over the previous close of $144.47 on the New York Stock Exchange. It has traded in the range of $96.04 to $161.99 in the last one year.

For comments and feedback contact: editorial@rttnews.com

Business News

Looking to Invest in the Best Biotech Stocks? Subscribe to RTT Biotech Investor.
Editors Pick
AbbVie (ABBV) Monday announced a collaboration and option-to-license agreement with Gilgamesh Pharmaceuticals, a clinical stage neuroscience biotech firm, to develop next-generation treatment approaches and unmet needs in psychiatric disorders. AbbVie noted that the first-generation compounds may... Healthwest Minerals, Inc. d/b/a Mt. Capra Products has recalled 1,506 boxes of Goat Milk Formula Recipe Kit, also urging consumers to immediately discontinue use of the product as infant formula. The firm does not recommend using this product for infants from 0-12 months of age. Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.

This week, we bring a mix of medical breakthroughs and setbacks. Lyko's MDMA therapy could become the first FDA-approved psychedelic treatment if all goes well as planned. A tragic loss occurred in Pfizer's Duchenne trial and a new study has raised concerns about ultra-processed foods. Find out why Long Beach declared a public health emergency and how Novavax's actions signal optimism.

View More Videos
Follow RTT